ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar

RecruitingOBSERVATIONAL

Enrollment

225

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions

Crohn DiseasePlaque Psoriasis

Interventions

DRUG

Ustekinumab 45 mg

biosimilar

DRUG

Ustekinumab 90 mg

biosimilar

Trial Locations (1)

RECRUITING

CHU Amiens, Amiens

All Listed Sponsors

collaborator

Sanoia

OTHER

lead

Celltrion HealthCare France

INDUSTRY

NCT06997055 - ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar | Biotech Hunter | Biotech Hunter